Theravance Biopharma (TBPH) Non-Current Debt (2018 - 2022)

Theravance Biopharma (TBPH) has 5 years of Non-Current Debt data on file, last reported at $396.1 million in Q2 2022.

• On a quarterly basis, Non-Current Debt rose 5.61% year-over-year to $396.1 million in Q2 2022; TTM through Jun 2022 was $396.1 million, a 5.61% increase from a year earlier, with the FY2021 full-year figure at $371.4 million, changed 0.41% from the prior year.
• Non-Current Debt for Q2 2022 stood at $396.1 million, up from $384.2 million in the prior quarter.
• Over the last five years, Non-Current Debt for TBPH reached as high as $396.1 million in Q2 2022 and fell as low as $217.7 million in Q2 2019.
• Historically, Non-Current Debt has averaged $326.3 million across 5 years, with a median of $373.9 million in 2020.
• Across the five-year window, Non-Current Debt declined 4.46% in 2019 and jumped 73.18% in 2020, its largest moves.
• Year by year, Non-Current Debt stood at $229.5 million in 2018, then retreated by 4.46% to $219.3 million in 2019, then jumped by 70.03% to $372.9 million in 2020, then declined by 0.41% to $371.4 million in 2021, then gained by 6.67% to $396.1 million in 2022.
• Per Business Quant data, the three most recent Non-Current Debt figures were $396.1 million in Q2 2022, $384.2 million in Q1 2022, and $371.4 million in Q4 2021.